Shahbazian Heshmatolah, Ghorbani Ali, Zafar-Mohtashami Azita, Balali Abdolreza, AleAli Armaghan, Lashkarara Gholam Reza
Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Internal Medicine, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khoramabad, Iran.
J Renal Inj Prev. 2016 Nov 26;6(1):61-64. doi: 10.15171/jrip.2017.11. eCollection 2017.
One of the most important causes of erythropoietin-resistant anemia in end-stage renal disease (ESRD) patients is increased levels of inflammatory cytokines. In this study pentoxifylline, an anti-inflammatory and anti-cytokine drug, with no significant side effects was used to manage anemia in ESRD patients. Thirty-nine ESRD patients with erythropoietin-resistant anemia were assigned to two groups, the treatment and the control groups. In treatment group, 19 patients received erythropoietin, venofer and pentoxifylline for 6 months. Patients in control group received erythropoietin and venofer. Hemoglobin (Hb), hematocrit (Hct), albumin and quantitative C-reactive protein (CRP) were measured at the beginning of the study, monthly and at the end of the study. Hb and Hct were significantly increased in the treatment group (9.33±1.25 g/dL and 28.08±3.88% at baseline; 11.22 ± 1.26 g/dL and 34.02 ± 3.72% at sixth month, = 0.01), but not in the control group. CRP was significantly decreased in the treatment group but no significant change occurred in the control group. Pentoxifylline is effective in improvement of erythropoietin-resistant anemia in ESRD patients.
终末期肾病（ESRD）患者中促红细胞生成素抵抗性贫血的最重要原因之一是炎症细胞因子水平升高。在本研究中，己酮可可碱，一种抗炎和抗细胞因子药物，无明显副作用，被用于治疗ESRD患者的贫血。39例促红细胞生成素抵抗性贫血的ESRD患者被分为两组，治疗组和对照组。治疗组中，19例患者接受促红细胞生成素、蔗糖铁和己酮可可碱治疗6个月。对照组患者接受促红细胞生成素和蔗糖铁治疗。在研究开始时、每月及研究结束时测量血红蛋白（Hb）、血细胞比容（Hct）、白蛋白和定量C反应蛋白（CRP）。治疗组的Hb和Hct显著升高（基线时分别为9.33±1.25 g/dL和28.08±3.88%；第六个月时分别为11.22±1.26 g/dL和34.02±3.72%，P = 0.01），而对照组则无显著变化。治疗组的CRP显著降低，而对照组无显著变化。己酮可可碱对改善ESRD患者的促红细胞生成素抵抗性贫血有效。
